chevron_leftBack
As of 13 June 2026, Achieve Life Sciences, Inc. has a market cap of $220.95M USD, ranking #20444 globally and #3356 in the United States.
It ranks #1831 in the Healthcare sector, and #668 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$220.95MUSD
Enterprise Value
$199.5MUSD
EBITDA (TTM)
-$54.65MUSD
Net Income (TTM)
-$54.65MUSD
PB Ratio
10.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Andrew Goldberg
open_in_new
Employees
28
Website
achievelifesciences.com
open_in_new
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.8% | -1.9% | 57% | -4.8% | -13% | 74% |
News
Loading...
ACHV Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ACHV
Achieve Life Sciences Inc
ISIN: US0044685008
Shares Out.:
Shares Outstanding:
102.659M1
Shares Float:
79.492M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
4.15 USD | |
|
SP4P
Achieve Life Sciences Inc
ISIN: US0044685008
|
3.58 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
345K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
248K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
163K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
124K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
68K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
53K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
145K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
131K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
124K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
82K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
50K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
49K%
80.96B GBP
|
14.6
|
chevron_leftBack